PegBio Co Ltd (2565) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of PegBio Co Ltd stock HK$2.70, price HK$3.25, that is 16.9% below the price, quality 46 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
PegBio Co Ltd
2565 · HKExpensive (fair value 17% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
18‑month range HK$3.08 – HK$74.65 · fair‑value band HK$2.02 – HK$3.37 · the HK$3.25 price screens above the HK$2.70 fair value. As of Nov 10, 2026.
Every Wednesday you see whether PegBio Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.
Show moreShow less
The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity.
It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia.
Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity.
PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
Stock analysis
PegBio Co Ltd (2565) currently trades at HK$3.25, while our estimate is HK$2.70, 17% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$2.02 (bear) to HK$3.37 (bull), the price of HK$3.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
PegBio Co Ltd reported revenue of 0 CNY in FY2025 versus 0 CNY in FY2022. Reported net income was −208M CNY in FY2025.
Key figures
Market cap HK$1.3B (≈ $162M) Micro · Return on equity −126% · Return on assets (EBIT) −77.8% (4-year average) · Operating margin 1,800% · Revenue (TTM) −HK$11.4M · Free cash flow −HK$156M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).
What moves the price
The share trades about 96% below its 52-week high and 6% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −17%, 2565 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare PegBio Co Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 2565 |
| Genmab A/S GMAB | kr 3,448 | kr 3,917 | +14% | vs 2565 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 2565 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 2565 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 2565 |
| CSL Limited CSL | A$202.92 | A$185.51 | −9% | vs 2565 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 2565 |
| Roivant Sciences Ltd ROIV | $39.53 | $19.47 | −51% | vs 2565 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 2565 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 2565 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is PegBio Co Ltd (2565) overvalued or undervalued?
What is the fair value of 2565?
What is the quality score of 2565?
What is the price target for PegBio Co Ltd (2565)?
What is the PegBio Co Ltd stock forecast for 2026?
What is the intrinsic value of PegBio Co Ltd (2565)?
Is PegBio Co Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2565?
How much is PegBio Co Ltd worth?
What do the bullish and bearish scenarios say about 2565?
How solid is the balance sheet of PegBio Co Ltd (2565)?
How far is 2565 from its 52-week high?
Which stocks are comparable to PegBio Co Ltd?
Is PegBio Co Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of PegBio Co Ltd (2565)?
What should I pay attention to with PegBio Co Ltd right now?
Key figures of PegBio Co Ltd
How large is the market capitalisation of PegBio Co Ltd (2565)?
What is the return on equity of PegBio Co Ltd (2565)?
What is the EBIT return on assets of PegBio Co Ltd (2565)?
What is the operating margin of PegBio Co Ltd (2565)?
How much revenue does PegBio Co Ltd (2565) generate?
How much free cash flow does PegBio Co Ltd (2565) generate?
Watch PegBio Co Ltd in the live analysis
One click puts PegBio Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.